Acadian Asset Management LLC Invests $1.07 Million in Zai Lab Limited Unsponsored ADR $ZLAB

Key Points

• Acadian Asset Management LLC invested approximately $1.07 million in Zai Lab Limited Unsponsored ADR by acquiring 29,693 shares, marking a significant new position for the firm.
• Multiple hedge funds are increasing their stakes in Zai Lab, including Kingsview Wealth Management, which boosted its position by 6.0%, indicating growing institutional interest in the company.
• Zai Lab shares have shown volatility, with a 12-month low of $20.17 and a high of $44.34, along with an average trading volume of about 791,592 shares.

Acadian Asset Management LLC acquired a new position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 29,693 shares of the company's stock, valued at approximately $1,073,000.

A number of other hedge funds have also recently bought and sold shares of the company. Kingsview Wealth Management LLC boosted its position in Zai Lab by 6.0% during the first quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock worth $337,000 after acquiring an additional 529 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Zai Lab in the 4th quarter valued at $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Zai Lab by 2.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock valued at $1,496,000 after purchasing an additional 1,200 shares during the last quarter. Walleye Capital LLC boosted its holdings in shares of Zai Lab by 6.4% in the 1st quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock valued at $805,000 after purchasing an additional 1,338 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zai Lab by 13.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock valued at $453,000 after purchasing an additional 1,483 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

Analyst Upgrades and Downgrades

ZLAB has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of Zai Lab in a report on Monday, August 25th. They issued a "buy" rating and a $52.00 price target on the stock. Wall Street Zen lowered Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Citigroup restated a "buy" rating and set a $69.00 price objective (up previously from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Finally, Leerink Partners set a $75.00 price objective on Zai Lab and gave the stock an "outperform" rating in a research note on Monday, June 30th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.35.

Insider Activity

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00. Following the completion of the transaction, the chief executive officer owned 536,962 shares in the company, valued at approximately $18,654,059.88. This represents a 8.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William Lis sold 13,814 shares of the company's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the transaction, the director owned 35,106 shares of the company's stock, valued at approximately $1,252,231.02. This trade represents a 28.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 215,710 shares of company stock worth $7,589,684 in the last quarter. Company insiders own 4.96% of the company's stock.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB traded up $0.42 during trading on Thursday, reaching $33.00. 405,831 shares of the company's stock traded hands, compared to its average volume of 791,592. Zai Lab Limited Unsponsored ADR has a 12 month low of $20.17 and a 12 month high of $44.34. The company has a 50 day moving average of $34.58 and a 200-day moving average of $33.97. The stock has a market capitalization of $3.69 billion, a P/E ratio of -16.18 and a beta of 1.04.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The business had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. Equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.